NCT00562913View on ClinicalTrials.gov

Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

March 31, 2010

Conditions
Cancer
Interventions
DRUG

Nexavar (Sorafenib, BAY43-9006)

Cyclophosphamide plus 400 mg BID sorafenib and doxorubicin

Trial Locations (2)

T6G 1Z2

Edmonton

H3T 1E2

Montreal

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00562913 - Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin | Biotech Hunter | Biotech Hunter